Response to Treatment with nab-Sirolimus in Patients with Perivascular Epithelioid Cell Sarcoma (PEComa) of Gynecologic or Peritoneal Origin: Subgroup Analysis from AMPECT

Home Response to Treatment with nab-Sirolimus in Patients with Perivascular Epithelioid Cell Sarcoma (PEComa) of Gynecologic or Peritoneal Origin: Subgroup Analysis from AMPECT

Response to Treatment with nab-Sirolimus in Patients with Perivascular Epithelioid Cell Sarcoma (PEComa) of Gynecologic or Peritoneal Origin: Subgroup Analysis from AMPECT

Response to Treatment with nab-Sirolimus in Patients with Perivascular Epithelioid Cell Sarcoma (PEComa) of Gynecologic or Peritoneal Origin: Subgroup Analysis from AMPECT

/ Publications

Share the Post

About the Author

Related Posts

Real-world (RW) characterization and frequency of TSC1 and/or TSC2 alterations collected from tumor tissue and liquid biopsies from the Tempus genomic database in patients with advanced cancer
nab-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer: A Phase 2, Open-Label, Single-Arm, Prospective, Multicenter Study
Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay” Summit
Management of adverse events in the AMPECT trial of nab-sirolimus for the treatment of advanced malignant perivascular epithelioid cell neoplasm (PEComa)
Aadi Bioscience Appoints Loretta Itri as Chief Medical Officer
Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Inactivating Alterations in TSC1 or TSC2 (PRECISION I)
Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer
Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement

Comments

Comments are closed.